"Bioidentical" is a statement about molecular structure. It means the hormone in the product has the same chemical structure as the one your ovaries made — 17-beta estradiol rather than conjugated equine estrogens, progesterone rather than medroxyprogesterone acetate. That is the entire definition. It says nothing about how the product was manufactured, whether anyone tested the batch, or whether it has been studied.

This matters because the term does two jobs at once in everyday use. It describes a real and clinically meaningful distinction between molecules. It also functions as a marketing category for compounded preparations that are not FDA-approved. Those two meanings get used interchangeably, and the confusion is where most bad decisions in this area come from.

The Verdict

The useful split is FDA-approved versus compounded, not bioidentical versus synthetic. FDA-approved bioidentical products already exist and cover most clinical needs: estradiol patches, gels, sprays, rings and tablets, plus oral micronized progesterone. The choices with real evidence behind them are transdermal over oral estrogen, because it avoids the first-pass clotting signal, and micronized progesterone over synthetic progestins in the breast-risk data. Both happen to be bioidentical. Compounded preparations are appropriate for documented allergies or genuinely non-standard doses, and a 2020 National Academies review found the evidence insufficient to support their general use.

Side by side

AttributeConventional HRTBioidentical hormone therapy
What the term means The umbrella term for menopausal hormone therapy; in common usage it points at older synthetic and animal-derived formulations Therapy using molecules structurally identical to human hormones — 17-beta estradiol, progesterone, testosterone
Typical molecules Conjugated equine estrogens; medroxyprogesterone acetate and other synthetic progestins 17-beta estradiol; micronized progesterone; estriol and estrone in some compounded blends
Source material Pharmaceutical synthesis, or extraction from pregnant mare urine for conjugated estrogens Plant sterols from yam or soy, chemically converted in a laboratory to the human molecule
FDA-approved products exist Yes — decades of approved products Yes — estradiol patches, gels, sprays, rings and tablets; oral micronized progesterone
Compounded versions exist Rarely; there is little demand for compounded synthetics Commonly — creams, troches, capsules and pellets prepared per prescription
Trial evidence base Large randomized trials including the Women's Health Initiative, with long follow-up FDA-approved bioidenticals are well studied; compounded preparations have not been tested in comparable trials
Batch consistency oversight FDA manufacturing standards apply FDA standards apply to approved products. Compounded preparations are not subject to the same pre-market testing, and potency has varied between batches in sampling studies
Typical monthly cost Generic conjugated estrogens and progestins are inexpensive and widely covered Generic estradiol patch roughly $15–$50 and micronized progesterone $20–$60, often covered. Compounded creams roughly $50–$150 and pellets $400–$800 per insertion, usually cash-pay

Where bioidentical hormones lead

  • Micronized progesterone has a different risk profile. Observational data has not shown the same breast-risk signal associated with some synthetic progestins.
  • Estradiol is a single defined molecule. Conjugated equine estrogens are a mixture of several estrogens whose individual contributions are harder to attribute.
  • Transdermal delivery is available in approved bioidentical form. Patches, gels and sprays deliver estradiol without the first-pass hepatic effect.
  • Serum levels are directly interpretable. A measured estradiol reflects what you took, which is not true of a conjugated estrogen mixture.
  • Micronized progesterone taken at night can help sleep, a side effect that works in the patient's favor during a stage when sleep disruption is common.

Where conventional formulations lead

  • The trial evidence is deeper. Conjugated equine estrogens are the most extensively trialled estrogen preparation, with decades of follow-up.
  • Bleeding control can be better. Some synthetic progestins manage the heavy bleeding of late perimenopause more reliably than micronized progesterone.
  • Endometrial protection is well characterised. Progestin dosing for endometrial safety has been studied across large populations and long durations.
  • Cost and availability are favorable. Generic conjugated estrogens and progestins are inexpensive, stocked everywhere, and widely covered by insurance.
  • Some formulations serve double duty in the transition, providing contraception alongside symptom control, which bioidentical regimens do not.

The choices that actually change risk

Both categories above contain good and poor options. What separates them in practice is not the label on the box.

ProductCategoryAdvantagesTrade-offs
Transdermal estradiol — patch, gel, spray FDA-approved bioidentical Bypasses first-pass liver metabolism; has not shown the venous thromboembolism signal associated with oral estrogen Skin reactions; patches can lift with heat or sweat
Oral estradiol FDA-approved bioidentical Inexpensive, simple to dose, widely stocked First-pass hepatic effect raises clotting factors relative to transdermal
Oral conjugated equine estrogens FDA-approved, not bioidentical The most extensively trialled estrogen preparation in existence A mixture of estrogens rather than a single molecule; same first-pass considerations as oral estradiol
Oral micronized progesterone FDA-approved bioidentical Endometrial protection; taken at night the sedative effect can help sleep Drowsiness; the standard formulation is suspended in peanut oil
Synthetic progestins FDA-approved, not bioidentical Reliable endometrial protection; some also control heavy transition bleeding Not interchangeable with micronized progesterone in the breast-risk data
Compounded estradiol or estriol creams and troches Compounded bioidentical Allows non-standard doses and avoids specific excipients when there is a documented allergy No pre-market potency testing; dose delivered can vary; endometrial protection harder to verify
Compounded hormone pellets Compounded bioidentical No recurring daily task once inserted Not FDA-approved for this use; levels frequently run supraphysiologic early and cannot be reduced without surgical removal
Low-dose vaginal estradiol — cream, tablet, ring FDA-approved bioidentical Treats genitourinary symptoms with minimal systemic absorption; a separate decision from systemic therapy Requires continued use, as symptoms return when it stops

Reading down that table, the pattern is consistent. Transdermal beats oral on venous thromboembolism risk regardless of which molecule is delivered. Micronized progesterone and synthetic progestins differ on breast risk. FDA-approved products have tested potency and compounded ones do not. None of those three distinctions maps onto the HRT-versus-BHRT framing that most of the marketing uses.

Timing matters more than formulation

Evidence supports a more favorable risk-benefit balance for systemic therapy started before age 60 or within about 10 years of the final period, compared with therapy started 15 or 20 years out. The proposed mechanism is that estrogen's vascular effect depends on the state of the arteries when exposure begins: supportive of endothelial function in relatively healthy vessels, less favorable where established plaque is already present.

Age-stratified re-analysis of the Women's Health Initiative found meaningfully different outcomes for women who began in their 50s compared with the trial's average participant at 63. This is why the choice between an estradiol patch and a compounded cream is a smaller decision than whether to have the conversation at 52 or at 66.

Contraindications and monitoring

These apply to systemic hormone therapy in any formulation, bioidentical or not.

  • Generally contraindicated: a history of breast cancer or other estrogen-sensitive cancer, unexplained vaginal bleeding, active liver disease, prior venous thromboembolism or stroke, known coronary heart disease, or a known thrombophilia.
  • Endometrial protection is mandatory for any woman with a uterus taking systemic estrogen. Unopposed estrogen raises endometrial cancer risk.
  • Low-dose vaginal estrogen is a separate decision. Systemic absorption is minimal, and it is appropriate for many women who cannot take systemic therapy.
  • Follow-up: a symptom and side-effect review at 6 to 12 weeks after starting or changing a dose, then at least annually, with blood pressure at each visit.
  • Screening does not change. Age-appropriate mammography and cervical screening continue on schedule.
  • Unscheduled bleeding gets evaluated, not dose-adjusted around.

How to decide

  1. Start with an FDA-approved product. Transdermal estradiol plus micronized progesterone if you have a uterus covers most situations, and both are generic and inexpensive.
  2. Choose the route on your risk profile. Transdermal is generally preferred with higher BMI, any clotting history, migraine with aura, or increasing age.
  3. Treat genitourinary symptoms separately. Low-dose vaginal estrogen addresses dryness, urgency and recurrent UTIs whether or not you take systemic therapy.
  4. Reserve compounding for a documented reason. An allergy to an excipient in every approved product, or a dose outside the approved range with a clinical rationale.
  5. Do not accept salivary testing as the basis for a dose. If a program's monitoring plan rests on it, ask what serum-based alternative it offers.
  6. Ask about the follow-up schedule before you start, because a set-and-forget prescription is the failure mode that spans every formulation on this page.

See a clinician rather than a prescribing service for bleeding after 12 months without a period, periods stopping before 45, a personal history of breast cancer or a clotting disorder, or if you are already on therapy and bleeding unexpectedly.

Frequently Asked Questions

What is the difference between HRT and BHRT?

HRT is the umbrella term for menopausal hormone therapy. In everyday use it has come to mean older formulations — conjugated equine estrogens and synthetic progestins. BHRT describes therapy using molecules structurally identical to human hormones: 17-beta estradiol, progesterone, testosterone. "Bioidentical" is a statement about molecular structure, nothing more. It says nothing about whether a product is FDA-approved, how it is manufactured, or how well it has been tested.

Are bioidentical hormones safer than conventional HRT?

The comparison that has evidence behind it is not bioidentical against synthetic. It is transdermal against oral, and micronized progesterone against synthetic progestins. Transdermal estradiol bypasses first-pass liver metabolism and has not shown the venous clotting signal seen with oral estrogen. Micronized progesterone and synthetic progestins differ in the breast-risk data. Both of those preferred options happen to be bioidentical, which is where the general claim comes from — but the reason is the route and the specific molecule, not the bioidentical label.

Is compounded BHRT different from FDA-approved bioidentical hormones?

Substantially. FDA-approved bioidentical products — estradiol patches, gels, sprays, rings, tablets, and oral micronized progesterone — are manufactured to federal standards, tested for potency and purity, and carry approved labelling. Compounded preparations are mixed per prescription and are not subject to the same pre-market testing. A 2020 National Academies review of compounded bioidentical hormone therapy found the evidence insufficient to support its general use and recommended restricting it to patients who cannot use an approved product.

Why are hormone pellets treated separately?

Compounded hormone pellets are not FDA-approved for menopausal hormone therapy. Published case series have reported supraphysiologic estradiol and testosterone levels after insertion, and a pellet dose cannot be reduced without surgical removal. Endometrial protection is also harder to verify in women with a uterus, because the estrogen exposure is fixed for months. The convenience is genuine; these are the specific reasons many specialist bodies do not treat them as a first-line option.

Do I need compounded hormones?

For most women, no. FDA-approved estradiol comes in patches, gels, sprays, rings and tablets across a wide range of doses, and micronized progesterone is available orally. Compounding is genuinely useful when there is a documented allergy to an excipient in every approved product, or when a dose outside the approved range is clinically justified. Outside those situations, the compounded route trades tested consistency for a customisation claim the evidence does not support.

Is saliva testing needed to dose bioidentical hormones?

No. Salivary hormone testing is not validated against serum for guiding hormone therapy dosing, and results correlate poorly with serum concentrations. It is often bundled with compounded preparations as a monitoring method. Standard practice for most regimens is to titrate against symptoms and side effects rather than to a target hormone level at all. Where a level is needed — testosterone in women, for instance — serum is the appropriate test.

What about the Women's Health Initiative — is hormone therapy risky?

The 2002 WHI results were reported in a way that produced widespread discontinuation, and prescribing fell by roughly 80%. The trial used oral conjugated equine estrogens with a synthetic progestin, and its average participant was 63 — more than a decade past menopause. Age-stratified re-analysis found meaningfully different results for women who started in their 50s. Current guidance supports systemic therapy for symptomatic women who start before age 60 or within 10 years of the final period, absent contraindications. Risk still exists and it is individual.

Until what age can you stay on hormone therapy?

There is no fixed stopping age in current guidance, and the arbitrary "five years then stop" rule that circulated after 2002 is no longer standard practice. What matters more than your age is the age at which you started. Continuing therapy begun at 51 into your sixties is a different risk calculation from starting fresh at 65, because the timing hypothesis concerns initiation rather than duration. The practical standard is an annual review with a prescriber covering symptoms, blood pressure, route, dose, and your current cardiovascular and breast cancer risk — with the default being to continue while benefit outweighs risk for you specifically.

When should you stop hormone therapy, and how?

Stop when the balance changes: a new contraindication appears, side effects persist after dose and route adjustment, or symptoms have resolved and you would prefer to trial without it. There is no evidence that abrupt discontinuation is dangerous, but roughly half of women see vasomotor symptoms return, and tapering the dose over several months rather than stopping outright reduces the rebound for many. Vaginal estrogen is a separate decision — it acts locally, genitourinary symptoms recur when it stops, and it is commonly continued indefinitely even after systemic therapy ends. Discuss the plan with a prescriber rather than stopping unilaterally.

Related